Loading...
Market
What will be the market share of Mounjaro vs. Ozempic by end of Q1 2025?
2
Resolution / Starting Odds
Mounjaro > 60% • 25%
Mounjaro 40-60% • 25%
Ozempic 40-60% • 25%
Ozempic > 60% • 25%
Market research reports and pharmaceutical sales data
Story
JAMA Internal Medicine Study: Mounjaro Leads to Greater Weight Loss Than Ozempic
Jul 8, 2024, 04:00 PM
A new study published in JAMA Internal Medicine has found that Eli Lilly's Mounjaro (tirzepatide) leads to significantly greater weight loss compared to Novo Nordisk's Ozempic (semaglutide). The study, which involved 20,000 participants, used real-world data and matched propensity analysis to compare the effectiveness of the two drugs. Results indicate that patients taking Mounjaro lost more weight than those on Ozempic, and the longer the treatment duration, the wider the gap in weight loss between the two groups. Additionally, tirzepatide, the active ingredient in Mounjaro, also outperformed semaglutide in Wegovy and Zepbound.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Mounjaro > 50% • 25%
Mounjaro 30-50% • 25%
Mounjaro 10-30% • 25%
Mounjaro < 10% • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Above 50% • 25%
30%-50% • 25%
10%-30% • 25%
Below 10% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%